Evidence map›Paper›PMID 17582004›Full record

ArticleJournal of virology2007

Inhibition of T-cell receptor signal transduction and viral expression by the linker for activation of T cells-interacting p12(I) protein of human T-cell leukemia/lymphoma virus type 1.

Risaku Fukumoto, Miroslav Dundr, Christophe Nicot, Anthony Adams, Valerio W Valeri, Lawrence E Samelson, Genoveffa Franchini

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Complete Rescue of HTLV-1Pathogens (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Risaku FukumotoAnimal Models and Retroviral Vaccines Section, National Cancer Institute, NIH, Bethesda, MD 20892-5065, USA.
Miroslav Dundr
Christophe Nicot
Anthony Adams
Valerio W Valeri
Lawrence E Samelson
Genoveffa Franchini
National Cancer Institute · US

Funding

APPLICATION OF FLOW CYTOMETRY TO CELL BIOLOGYZ01BC009255 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHARROW, SUSAN · 1996 to 2008
$3.0M
Uncoupling of Jak/STAT in HTLV-1 associated leukemiaR01CA115398 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NICOT, CHRISTOPHE P · 2007 to 2011
$1.3M
Intramural NIH HHSNCI NIH HHS CA115398NCI NIH HHS R01 CA115398
6 · The paper itself

Abstract

The p12(I) protein of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) is a small oncoprotein that increases calcium release following protein kinase C activation by phorbol myristate acetate, and importantly, this effect is linker for activation of T cells (LAT) independent. Here, we demonstrate that p12(I) inhibits the phosphorylation of LAT, Vav, and phospholipase C-gamma 1 and decreases NFAT (nuclear factor of activated T cells) activation upon engagement of the T-cell receptor (TCR) with anti-CD3 antibody. Furthermore, we demonstrate that p12(I) localizes to membrane lipid rafts and, upon engagement of the TCR, relocalizes to the interface between T cells and antigen-presenting cells, defined as the immunological synapse. A p12(I) knockout molecular clone of HTLV-1 expresses more virus upon antigen stimulation than the isogenic wild type, suggesting that, by decreasing T-cell responsiveness, p12(I) curtails viral expression. Thus, p12(I) has contrasting effects on TCR signaling: it down-regulates TCR in a LAT-dependent manner on one hand, and on the other, it increases calcium release in a LAT-independent manner. The negative regulation of T-cell activation by p12(I) may have evolved to minimize immune recognition of infected CD4(+) T cells, to impair the function of infected cytotoxic CD8(+) T cells, and to favor viral persistence in the infected host.

Indexed as

Adaptor Proteins, Signal TransducingCell LineDown-RegulationGene DeletionHumansHuman T-lymphotropic virus 1Membrane MicrodomainsMembrane ProteinsNFATC Transcription FactorsOncogene Proteins, ViralPhospholipase C gammaPhosphorylationProto-Oncogene Proteins c-vavReceptors, Antigen, T-CellSignal TransductionTranscription FactorsAdaptor Proteins, Signal TransducingLAT protein, humanMembrane ProteinsNFATC Transcription FactorsOncogene Proteins, Viralp12I protein, Human T-lymphotropic virus 1Phospholipase C gammaProto-Oncogene Proteins c-vavReceptors, Antigen, T-CellTranscription FactorsViral Regulatory and Accessory Proteins

Identifiers

PMID17582004
PMCPMC1951423
OpenAlexW2067661362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.